Governed AI Across Clinical Development
Govern AI execution across protocol, data, and submission workflows — end to end.
A Day in the Life of a Head of Clinical Development
Two programs are running in parallel across multiple therapeutic areas. The portfolio review is in three days. One asset has a protocol amendment in flight. Another has a data signal that needs cross-functional triage by end of week.
Execution variability — not science — is what is putting the program timeline at risk. Coordination across functions and vendors absorbs the calendar.
Maxis AI standardizes execution across programs so leadership time goes back to development decisions.
Human-in-the-loop validation · Audit traceability · Governed execution
The Pressures Clinical Development Leaders Carry Every Day
Inconsistent Execution
Execution varies across studies, therapeutic areas and CROs — leadership absorbs the gap through escalation and rework.
Reactive Risk Posture
Risks are detected earlier than ever, but resolution is still manual. Mitigation runs after the milestone has already moved.
Pilots Without Production
AI pilots demonstrate insight in isolation but rarely reach validated, governed production execution across the portfolio.
Clinical development needs governed execution capacity — not more dashboards or pilots.
Industry Reality
- Protocol complexity continues to rise across therapeutic areas.
- Site networks expand globally, multiplying coordination load.
- Regulatory oversight tightens across regions and modalities.
- Data volume across clinical systems grows faster than review capacity.
- Workforce constraints persist; headcount scaling is not the answer.
Development organizations need an operating model that scales without proportional headcount growth.
How Maxis AI Is Built for Clinical Development
Maxis AI deploys an AI workforce of supervised agents that execute development workflows across study design, conduct, data and reporting. Every workflow is governed under GxP, 21 CFR Part 11, ICH-GCP and SOC 2 Type II.
Standardized execution across programs replaces variable, person-dependent coordination — and outcomes are measurable against development KPIs.
From Pain to Outcome: How Maxis AI Works for You
Pain Point
AI Capability
Outcome
Inconsistent execution across studies and TAs.
Supervised execution patterns standardized across programs.
Predictable execution across the portfolio.
Manual coordination across functions and vendors.
Cross-functional agent workflows with audit trails.
Reduced coordination overhead and escalation load.
Reactive risk detection after slippage.
Continuous monitoring agents with structured intervention.
Earlier detection with governed, repeatable response.
Heavy escalation load on senior leaders.
Agent-driven workflow execution under supervision.
Leadership returned to development decisions.
Pilots that don't reach validated production use.
Production-grade governed execution layer.
AI deployed across programs under real audit conditions.
Simplified Trial Protocol by 25% and Reduced Study Duration by ~6 Months
Find out how clinical development improved adaptive decision-making in a complex Phase II study with 150–200+ endpoints, slow interim analysis cycles, and rising amendment risk.
32%
Lower Escalation Load
2.6x
Execution Throughput
100%
Audit Traceability
0
System Replacements
All You Need to Know
It operates as a supervised execution layer aligned to GxP, 21 CFR Part 11 and ICH-GCP, with audit traceability across every action.
No. Maxis AI integrates with EDC, CTMS, eTMF, safety and imaging platforms — no rip-and-replace.
Reviewers retain approval authority through defined supervision checkpoints across every governed workflow.
Standardization across programs, startup predictability and reduced escalation overhead.
Yes. Throughput and consistency gains compound as data volume and complexity increase.
Explore the Agentic AI Platform.
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.